Company Celyad Oncology SA

Equities

CYAD

BE0974260896

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 11:35:10 2024-04-24 am EDT			5-day change	1st Jan Change
0.32 ^EUR	-3.03%		-5.74%	-17.95%

Apr. 04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 09	Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	MT

Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Number of employees: 18

EUR in Million	2022	Weight	2023	Weight	Delta
Cardiology 100.0 %	0	nan %	0	100.0 %	-

EUR in Million	2022	Weight	2023	Weight	Delta
Europe and United States 100.0 %	0	nan %	0	100.0 %	-

Managers	Title	Age	Since
Michel Lussier FOU	Founder	67	07-07-23
David Georges DFI	Director of Finance/CFO	-	18-12-31
Eytan Breman CTO	Chief Tech/Sci/R&D Officer	-	14-12-31
An Phan LAW	General Counsel	49	21-08-31

Members of the board	Title	Age	Since
Michel Lussier FOU	Founder	67	07-07-23
Hilde Windels CHM	Chairman	59	18-05-06
Serge Goblet BRD	Director/Board Member	-	07-12-31
J. Christopher LiPuma BRD	Director/Board Member	53	22-01-19
Jonathan M. James BRD	Director/Board Member	-	-
Dominic Piscitelli BRD	Director/Board Member	50	20-05-05
Sage Mandel BRD	Director/Board Member	-	-
Marina Udier BRD	Director/Board Member	-	11-01-10
Ami Patel Shah BRD	Director/Board Member	-	21-12-07

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	41,428,572	38,267,083 ( 92.37 %)	0	92.37 %

Name	Equities	%	Valuation
Tolefi SA 5.541 %	2,295,701	5.541 %	870 254 €
Michel Lussier 0.3779 %	156,550	0.3779 %	59 345 €
OP Asset Management Ltd. 0.2571 %	106,527	0.2571 %	40 382 €
C Worldwide Asset Management Fondsmæglerselskab A/S (Sweden) 0.1840 %	76,235	0.1840 %	28 899 €
BNP Paribas Asset Management Belgium SA 0.1753 %	72,641	0.1753 %	27 537 €
Serge Goblet 0.1356 %	56,180	0.1356 %	21 297 €
Ecofi Investissements SA 0.0818 %	33,899	0.0818 %	12 850 €
Claresco Finance SA 0.0791 %	32,789	0.0791 %	12 430 €
Gestys SA 0.0676 %	28,000	0.0676 %	10 614 €
Puilaetco Dewaay Private Bankers SA 0.0394 %	16,313	0.0394 %	6 184 €

Celyad Oncology SA

Axis Business Park Rue André Dumont 9

1435, Mont-Saint-Guibert

+32 1 039 41 00

http://www.celyad.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELYAD ONCOLOGY SA	-17.95%	14.63M
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B

Other Biotechnology & Medical Research